CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation

After bone marrow transplantation (BMT) using T-cell–depleted marrow from an unrelated donor or HLA-mismatched related donor, the risk of developing lymphoproliferative disease associated with the Epstein-Barr virus (EBV) ranges from 1% to 25%. We have shown that administration of donor-derived EBV-...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2000-02, Vol.95 (4), p.1502-1505
Main Authors: Kuehnle, Ingrid, Huls, M. Helen, Liu, Zhensheng, Semmelmann, Micah, Krance, Robert A., Brenner, Malcolm K., Rooney, Cliona M., Heslop, Helen E.
Format: Article
Language:English
Subjects:
Adolescent
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20 - immunology
Antineoplastic agents
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Bone Marrow Transplantation
Child, Preschool
Disease-Free Survival
Hematopoietic Stem Cell Transplantation
Herpesvirus 4, Human - isolation & purification
Humans
Immunophenotyping
Immunotherapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - therapy
Lymphocytes - immunology
Lymphoma - drug therapy
Lymphoma - therapy
Male
Medical sciences
Pharmacology. Drug treatments
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
Rituximab
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:After bone marrow transplantation (BMT) using T-cell–depleted marrow from an unrelated donor or HLA-mismatched related donor, the risk of developing lymphoproliferative disease associated with the Epstein-Barr virus (EBV) ranges from 1% to 25%. We have shown that administration of donor-derived EBV-specific cytotoxic T lymphocytes (CTL) is effective prophylaxis and treatment for this complication, and we routinely generate CTL for high-risk patients. However, EBV lymphoma can occur in recipients of matched-sibling transplants for whom CTL are unavailable or in patients for whom CTL administration is contraindicated. We report on 3 such patients, who were successfully and safely treated with rituximab, a CD20 monoclonal antibody. The patients remain disease free 7, 8, and 9 months, respectively, after therapy. We conclude that CD20 antibody may be a useful alternative treatment strategy in patients with EBV lymphoma after BMT.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V95.4.1502.004k40_1502_1505